Epstein-Barr Virus Infections Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

Also known as: Epstein-Barr Virus Infection / EBV Infections / EBV Infection / Epstein-Barr viral infections

IndicationStatusPhase
DBCOND0029759 (Epstein-Barr Virus Infections)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03769467Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Treatment